Sengenics Corporation Announces Yvonne Linney, PhD as New Board Director

2023-01-09

高管变更

BOSTON & STOCKHOLM--(BUSINESS WIRE)--Sengenics Corporation LLC, driving the discovery of next-gen biomarkers through its immuno-proteomic platform, KREX®, and Summa Equity announce that Yvonne Linney PhD. has been appointed to the company’s Board of Directors, effective immediately. With more than 30 years of experience in bioscience markets for life science research, diagnostics and analytical products, Dr Linney promises to help build on Sengenics’ growth in the fields of immunology, immuno-oncology, neurological disease, and precision medicine.

'Sengenics is an early pioneer in autoantibody detection for life science research, drug development and precision medicine'

“We welcome Dr. Linney to the Board as a new independent Director and look forward to the leadership she will bring,” said Nick Roelofs, PhD., Chairman of Sengenics and Partner at Summa Equity. “We are pleased to add her deep knowledge in life science markets and her breadth of expertise leading both private and public companies to the Board.”

Dr Linney is a proven business leader who has successfully brought emerging technologies to market and grown their adoption in the life science markets. She has previously held executive roles at Agilent Technologies (A) Life Sciences Group and Amersham International (GE Healthcare), as well as more recently CEO and COO roles at venture-based companies, Transcriptic (Strateos) and Artificial Inc. She is also a member of the Board of Directors of Bionano Genomics Inc (BNGO).

“Sengenics is an early pioneer in autoantibody detection for life science research, drug development and precision medicine,” said Dr. Linney. “It is an exciting time for the Company, and I am eager to be part of the team as they continue to address the significant unmet medical needs of patients suffering from cancer, autoimmune disease, and neurological disorders through their premier immuno-proteomic platform, KREX,” commented Dr. Linney.

About Sengenics

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics. Sengenics Corporation LLC is headquartered in Greater Boston, Massachusetts, USA and has offices worldwide. Sengenics has more than 50 employees across its current locations. www.sengenics.com

About Summa Equity

Summa Equity invests in companies that are solving global challenges and creating positive Environmental, Social, and Governance (ESG) outcomes for society. Summa’s purpose is to co-create win-win for investors, portfolio companies, and society through aligning its vision and outcomes to the Sustainable Development Goals, ensuring a net-positive impact against ESG challenges, and the potential for long-term, sustainable outperformance. Investments are focused on industries and companies that have tailwind from megatrends within three sustainability themes: Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. Across these themes, Summa’s portfolio companies are supporting a world in transition and showing that business can be part of the solution. Summa Equity has c. EUR 4 billion (c. SEK 40 billion) assets under management. www.summaequity.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构